Vanguard Fiduciary Trust
CYCN icon

Vanguard Fiduciary Trust’s Cyclerion Therapeutics CYCN Stock Holding History

Vanguard Fiduciary Trust’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.9K Hold
7,353
– – ﹤0.01% 3970
2026
Q1 		$11.3K Buy
+7,353
New +$10.5K ﹤0.01% 3992

Other funds holding CYCN

KCM
Kalehua Capital Management Dallas, Texas $140M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RC
Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Vanguard Fiduciary Trust's CYCN Position: Q2 2026 in Review

Vanguard Fiduciary Trust held its Cyclerion Therapeutics (CYCN) position steady in Q2 2026 at 7,353 shares worth $24.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3970.

Vanguard Fiduciary Trust first reported a position in CYCN in Q1 2026 and has held it in 2 quarters since. 21 funds tracked by Wall St. Rank hold CYCN as of Q2 2026.

  • Vanguard Fiduciary Trust held 7,353 shares of Cyclerion Therapeutics worth $24.9K as of Q2 2026.
  • Vanguard Fiduciary Trust left its Cyclerion Therapeutics share count unchanged in Q2 2026.
  • Cyclerion Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3970 holding.
  • Vanguard Fiduciary Trust first reported a position in Cyclerion Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 21 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.